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Abstract
Background Muscle wasting and unintentional weight loss (cachexia) have been associated with worse outcomes in heart
failure (HF), but timely identification of these adverse phenomena is difficult. Spot urinary creatinine may be an easily acces-
sible marker to assess muscle loss and cachexia. This study investigated the association of urinary creatinine with body com-
position changes and outcomes in patients with new-onset or worsening HF (WHF).
Methods In BIOSTAT-CHF, baseline spot urinary creatinine measurements were available in 2315 patients with new-onset or
WHF in an international cohort (index cohort) and a validation cohort of 1431 similar patients from Scotland.
Results Median spot urinary creatinine concentrations were 5.2 [2.7–9.6] mmol/L in the index cohort. Median age was
69 ± 12 years and 73% were men. Lower spot urinary creatinine was associated with older age, lower height and weight, worse
renal function, more severe HF, and a higher risk of >5% weight loss from baseline to 9 months (odds ratio = 1.23, 95%
CI = 1.09–1.39 per log decrease; P = 0.001). Spot urinary creatinine was associated with Evans criteria of cachexia
(OR = 1.26 per log decrease, 95% CI = 1.04–1.49; P = 0.016) and clustered with markers of heart failure severity in hierarchical
cluster analyses. Lower urinary creatinine was associated with poorer exercise capacity and quality of life (both P< 0.001) and
predicted a higher rate for all-cause mortality [hazard ratio (HR) = 1.27, 95% CI = 1.17–1.38 per log decrease; P < 0.001] and
the combined endpoints HF hospitalization or all-cause mortality (HR = 1.23, 95% CI = 1.15–1.31 per log decrease; P < 0.001).
Significance was lost after addition of the BIOSTAT risk model. Analyses of the validation cohort yielded similar findings.
Conclusions Lower spot urinary creatinine is associated with smaller body dimensions, renal dysfunction, and more severe
HF in patients with new-onset/WHF. Additionally, lower spot urinary creatinine is associated with an increased risk of weight
loss and a poorer exercise capacity/quality of life. Urinary creatinine could therefore be a novel, easily obtainable marker to
assess (risk of) muscle wasting in HF patients.
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Introduction
Unintentional weight loss or cachexia is common in heart fail-
ure (HF) and associated with adverse outcomes.1–3 A state of
cachexia may reflect underlying muscle loss (in addition to fat
or bone tissue loss), which is associated with decreased exer-
cise capacity, reduced muscle strength, and a worse outcome
in patients with HF.4,5 However, subclinical muscle wasting
does not always result in lower body weight and can often
go undetected.6 Patients who are obese or of normal body
weight may still have underlying muscle wasting,6,7 and oe-
dema may also mask underlying muscle breakdown. Concen-
trations of serum creatinine, produced after stable
conversion of creatine largely found in skeletal muscles, are
generally used to estimate glomerular filtration rate. How-
ever, provided that renal function, physical activity, and die-
tary protein intake remain consistent, it can also be used as
a marker to reflect (peripheral) muscle catabolism.8 Cur-
rently, 24 h creatinine excretion rate is used as a measure
of muscle wasting, and recent studies have shown that lower
urinary creatinine is an independent predictor of worse out-
comes in the general population and in various chronic ill-
nesses such as HF, coronary artery disease, diabetes
mellitus, and chronic kidney disease.9–14
Even though 24 h urine collection is a reliable measure of
muscle breakdown, it is a time-consuming procedure and of-
ten inconvenient for patients.15,16 In a recent analysis of the
GISSI-HF study, we showed that morning spot urinary creati-
nine, an inexpensive and easily accessible marker, was associ-
ated with smaller body dimensions and worse outcomes in
chronic HF.15 However, previous studies have not investi-
gated its role in patients with acute/worsening HF (WHF). In
addition, the association between spot urinary creatinine
and weight loss over time has not yet been studied in pa-
tients with HF. Therefore, the aims of the current study were
to investigate the value of spot urinary creatinine (as a
marker of muscle wasting) in new-onset or WHF patients,
to predict outcomes and to evaluate its association with
weight loss. We hypothesize that lower urinary creatinine
may be an easily obtainable marker to identify HF patients
at risk of muscle wasting, who might ultimately benefit from
interventions aimed at increasing muscle mass.
Methods
Study population
Study design and results of BIOSTAT-CHF (A systems BIOlogy
Study to Tailored Treatment in Chronic Heart Failure) have
been previously published.17–19 Briefly, in the multicentre,
prospective, observational study, 2516 patients with
new-onset HF or WHF were enrolled. The validation cohort
enrolled 1738 patients from Scotland, UK. Recruited patients
were receiving oral or intravenous furosemide ≥40 mg/day or
equivalents, had left ventricular ejection fraction
(LVEF) ≤ 40%, or had brain natriuretic peptide (BNP) concen-
trations >400 pg/mL and/or N-terminal pro-B-type natri-
uretic peptide (NT-proBNP) concentrations >2000 pg/mL at
the time of inclusion. Both inpatients and outpatients were
enrolled, but most patients had worsening signs/symptoms
of chronic HF (WHF), and the rest had new-onset HF.17 Inves-
tigators were encouraged to initiate new evidence-based
therapies or uptitrate current therapies in the first 3 months
of the study, followed by a 6-month period of maintenance
phase. The study was conducted according to the Declaration
of Helsinki and was approved by all local and national ethical
committees. All patients provided written informed consent.
Study assessments
Baseline spot urinary creatinine measurements were avail-
able in 2315 (92%) patients in the index cohort and 1431
(82%) patients in the validation cohort. The exact timing of
spot urinary measurements was not specified in the study
protocol. Patients missing baseline urinary creatinine were
excluded (n = 201 for the index cohort and n = 307 for the
validation cohort). Baseline characteristics according to in-
cluded and excluded patients for index and validation cohort
have been shown in Supporting Information, Tables S1 and
S2. Urinary samples were stored at 80°C until measurement
at the clinical laboratory of University Medical Center
Groningen using the Roche Cobas® analyser. Measurements
of neutrophil gelatinase-associated lipocalin (NGAL) were
performed at the laboratory of University Medical Center
Utrecht, using a Luminex-based in-house developed and vali-
dated multiplex immunoassay (xMAP; Luminex, Austin, TX
previously published).20 N-terminal pro-brain natriuretic pep-
tide (NT-proBNP) concentrations were measured using
electrochemiluminescence on a Cobas e411 analyser (Roche
Diagnostics GmbH, Mannheim, Germany).19 All other bio-
markers were measured as published previously.19,21 Esti-
mated glomerular filtration rate (eGFR) was calculated using
the simplified Modification of Diet in Renal Disease (MDRD)
formula. Weight was measured at baseline and at 9 months.
Weight loss or weight gain was defined as difference in
weight between baseline and 9 months; furthermore, weight
loss or weight gain greater than 5% within 9 months was cal-
culated (Fearon’s criteria for cachexia).22 Lastly, we used the
Evans criteria for cachexia, which includes weight loss >5%
from baseline to 9 months and C-reactive protein
(CRP) > 5 mg/L or interleukin-6 (IL6) > 4 pg/mL,
haemoglobin <7.45 mmol/L, and albumin <32 d/L.23 The
6-min walking test was used as a measure of physical activity
in the index cohort; however, this was unavailable in the val-
idation cohort. For the index cohort, a clinical congestion
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score (range from 0 to 5) was defined as the sum of jugular
venous pressure (JVP) (0 to 1), extent of peripheral oedema
(0, 1/3, 2/3, or 1) and orthopnoea (0 to 1), with a maximum
score of 4 in the validation cohort, as orthopnoea was not
assessed in this cohort.19
Statistical analysis
Baseline characteristics were summarized according to quar-
tiles of urinary creatinine for the index and validation cohort.
Categorical variables were summarized as frequency (per-
centages) and continuous variables as mean ± standard devi-
ation or as median [inter-quartile range] based on normal/
skewed distribution. Differences between quartiles of spot
urinary creatinine were tested for significance using Fisher’s
exact test for categorical variables, Kruskal–Wallis test for
continuous skewed variables, and analysis of variance
(ANOVA) for continuous normally distributed variables.
Trends over quartiles were tested with Cochran–Armitage
trend test for categorical variables, Jonckheere–Terpstra for
non-normally distributed variables, and linear regression
model for normally distributed variables. Non-normally dis-
tributed variables were log transformed or standardized for
further analyses where necessary. The association of baseline
clinical variables with baseline urinary creatinine concentra-
tions and percentage change in weight were investigated in
univariable and multivariable linear regression models. Trans-
formations were verified using multifractional polynomials.
All variables with a P-value < 0.10 in univariable analyses
were included in the multivariable models. Multivariable re-
gression models were constructed via backward elimination
and validated using 1000 replicate bootstrap re-sampling.
The correlation heatmaps and dendrograms were con-
structed using the ggplot2, reshape2, fastcluster, Hmisc, and
sparcl packages in R. The association between spot urinary
creatinine and weight loss was investigated using a
univariable logistic regression model. The association of spot
urinary creatinine concentrations with endpoints all-cause
mortality and the combined endpoint all-cause mortality
and first occurrence of HF rehospitalisation was assessed
using Cox regression hazards proportional analysis. Propor-
tional hazards assumptions were checked using log–log plots
and Schoenfeld residuals. Models were adjusted for body
mass index (BMI), age, sex, eGFR, and loop diuretic doses at
baseline. Following this, the outcome analyses were adjusted
for the respective previously published models for all-cause
mortality, and the combined endpoint of all-cause mortality
and heart failure hospitalization.24 Kaplan–Meier curves were
used to investigate prognostic ability of urinary creatinine
concentrations and weight loss for the endpoints. Differences
between groups were tested using a log-rank test. A
two-tailed P value < 0.05 was considered statistically signifi-
cant. All analyses were performed using R: a Language and
Environment for Statistical Computing, version 3.5.1
(R Foundation for Statistical Computing, Vienna, Austria).
Results
Baseline characteristics index cohort
Baseline characteristics of the index cohort according to uri-
nary creatinine quartiles are shown in Table 1. Briefly, mean
age was 69 (±12) years, 73% (1696) of the patients were
men, 60% had a NYHA class III/IV, and mean LVEF was 31%
(±9.9%). Median urinary creatinine concentrations were 5.2
[2.7–9.6] mmol/L in the index cohort. Lower urinary creati-
nine concentrations were associated with older age and
smaller body dimensions (lower height, weight and BMI at
baseline and at 9 months, P < 0.001) (Table 1). Patients in
the lowest urinary creatinine quartile were more likely to
have severe HF (worse NYHA class and higher NT-proBNP
concentrations, P < 0.001), signs and symptoms of conges-
tion such as oedema, orthopnoea, rales, elevated JVP, hepa-
tomegaly, elevated clinical congestion score (all P < 0.032),
and poorer renal function (low eGFR and high BUN concen-
trations, all P < 0.001) (Table 1). There was no significant dif-
ference in loop diuretic use and LVEF across the quartiles;
however, patients with lower urinary creatinine did require
higher doses of loop diuretics. These patients also had a
higher urinary sodium-to-creatinine ratio (P < 0.001) (Table
1). Men had higher urinary creatinine concentrations com-
pared with women (P < 0.001) (Table 1). Patients from the
lowest creatinine quartile were significantly more likely to
have >5% weight loss over a period of 9 months
(P < 0.001) (Table 1, Figure 1). Interestingly, patients with
lower urinary creatinine concentrations had a significantly
lower exercise capacity, as assessed by the 6-min walking test
(P < 0.001), and experienced a poorer quality of life as
assessed by the EuroQol five dimension visual analogue scale
(EQ-5D VAS) and Kansas City Cardiomyopathy Questionnaire
(KCCQ) (P < 0.001) (Table 1). Not only urinary creatinine
but also weight loss was an independent predictor of lower
exercise capacity.
Baseline predictors of urinary creatinine
concentrations and hierarchical cluster analysis
Predictors of urinary creatinine concentrations in the index
cohort are presented in Table 2. In a multivariable linear re-
gression model, lower spot urinary creatinine was associated
with higher plasma NT-proBNP, female sex, lower diastolic
blood pressure, lower plasma sodium, and was borderline
non-significant for oedema and orthopnoea (r2 = 0.06) (Table
2). The results of hierarchical clustering of variables and a
Urinary creatinine in new-onset and worsening HF 3
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correlation heatmap for the index cohort are presented in
Figures 2 and 3, respectively. In a hierarchical cluster analysis
(Figure 2), urinary creatinine clustered with NT-proBNP and
troponin T. Interestingly, urinary creatinine did not cluster
with BMI or albumin. The heatmap (Figure 3) illustrates that
urinary creatinine concentrations are most strongly corre-
lated with FGF23 (Spearman’s rho: 0.25, P < 0.001),
GDF-15 (Spearman’s rho: 0.24, P < 0.001), and
NT-proBNP (Spearman’s rho: 0.24, P < 0.001).
Urinary creatinine and weight loss
Lower urinary creatinine was a significant predictor of
weight loss at 9 months [odds ratio (OR) = 1.14, 95%
CI = 1.03–1.27 per log decrease; P = 0.015], and especially
a risk of more than 5% weight loss in 9 months
(OR = 1.23, 95% CI = 1.09–1.39 per log decrease;
P = 0.001) (Table 3). Lower urinary creatinine was also a sig-
nificant predictor of a more stringent definition of cachexia
(Evans’ criteria), which incorporates abnormal biochemistry
(OR = 1.26 per log decrease, 95% CI = 1.04–1.49;
P = 0.016) (Table 3). As shown in Supporting Information,
Table S3, in a multivariable model of weight loss including
BMI, NT-proBNP, and urinary creatinine, urinary creatinine
was non-significant (P = 0.064).
Urinary creatinine and outcomes
During a median follow-up of 21 months (16–27 months), out
of 2315 patients, 61 (26.4%) died and 950 (41.0%) experi-
enced the combined endpoint mortality and/or HF hospitali-
zation. In a univariable Cox regression model, lower urinary
creatinine was significantly associated with higher all-cause
mortality [hazard ratio (HR = 1.27, 95% CI = 1.17–1.38 per
log decrease; P < 0.001] and the combined endpoint of
all-cause mortality and HF hospitalization (HR = 1.23, 95%
CI = 1.15–1.31 per log decrease; P < 0.001) (Table 4, Figure
4). The associations remained significant even after adjusting
for BMI, age, sex, eGFR, and baseline loop diuretic dose. The
association was, however, attenuated after additional adjust-
ment for the BIOSTAT risk model (Table 4). Lastly, a decrease
in weight from baseline to 9 months and >5% weight loss
predicted a higher risk of combined endpoint (Supporting
Figure 1 Percentage of patients with or without more than 5% weight loss (in 9 months) per quartile of urinary creatinine (index cohort).
Table 2 Multivariable linear regression model for predictors of baseline




coefficient T value P-value
DBP 0.095 3.654 <0.001
Plasma sodium 0.075 2.667 0.008
Plasma BUN 0.050 1.786 0.074
Peripheral oedema above ankle 0.109 1.788 0.074
Orthopnoea 0.110 1.885 0.060
Plasma NT-proBNP 0.068 2.356 0.019
Female sex 0.207 3.366 0.001
BUN, blood urea nitrogen; DBP, diastolic blood pressure; NT-
proBNP, N-terminal pro-brain natriuretic peptide.
ar2 = 0.06, continuous variables are presented per standard
deviation.
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Information, Figures S1 and S2). This, however, did not re-
main significant after adjustment for urinary creatinine
(P = 0.105) or after adjustment for the BIOSTAT risk model
(P = 0.522).
Validation cohort
Median urinary creatinine was 3.9 (2.1–7.2) mmol/L. Mean
age was 75 ± 11 years, 68.4% (979) of the patients were
men, and mean LVEF was 41 ± 13. Patients with lower urinary
creatinine had lower height, weight, and BMI (all P < 0.008)
and were more often women (P < 0.001). Patients in this
group had more severe HF [worse NYHA class, higher
NT-proBNP concentrations, more rales (all P < 0.021)], and
higher urinary sodium/creatinine ratio (P< 0.001) (Supporting
Information, Table S4). In a multivariable model, per log
decrease in urinary creatinine was associated with lower
height, weight, and plasma sodium (Supporting Information,
Table S5). In hierarchical cluster analysis (Supporting
Information, Figure S3), urinary creatinine clustered with
potassium and was part of a greater cluster that included
albumin and BMI. The heatmap (Supporting Information,
Figure S4) showed that urinary creatinine was correlated with
NT-proBNP (Spearman’s rho: 0.13, P < 0.001) and sodium
(Spearman’s rho: 0.12, P < 0.001). Lower urinary creatinine
was associated with a greater risk of all-cause mortality
(HR = 1.13, 95% CI = 1.01–1.27 per log decrease; P = 0.039)
and the combined endpoint (HR = 1.16, 95% CI = 1.05–1.28
per log decrease; P = 0.004, Supporting Information,
Figure S5), even after adjusting for BMI, age, sex, eGFR, and
loop diuretic dose but was attenuated after adjusting for
BIOSTAT risk score (Supporting Information, Table S6).
Discussion
In this study, we showed that in patients with new-onset/
worsening HF, lower spot urinary creatinine concentrations
were associated with smaller body dimensions, renal dys-
function, and more advanced HF. Furthermore, lower urinary
creatinine was associated with an increased risk of weight
loss and adverse outcomes in patients with new-onset/
worsening HF. These findings were validated in an external
cohort yielding similar findings.
Spot urinary creatinine, weight loss, and muscle
wasting in new-onset/worsening heart failure
Measurement of creatinine concentrations in a 24 h urine
sample may be a useful marker to estimate muscle loss, as it
is produced after stable conversion of creatine, which is mostly
found in skeletal muscles.8 The reliability of 24 h urinary creat-
inine excretion as a measure of muscle wasting has been
investigated in several chronic illness populations9–14 and
correlated with muscle mass measured using different
techniques, including bioimpedance analysis, computerized
Figure 2 Biomarker position of spot urinary creatinine depicted in hierarchical cluster analysis (index cohort). Abbreviations: Bio-ADM, biologically ac-
tive adrenomedullin; BMI, body mass index; CRP, C-reactive protein; FGF23, fibroblast growth factor 23; GDF15, growth differentiation factor 15; GFR,
glomerular filtration rate; HDL, high density lipoprotein; IL6, interleukin-6; LDL, low density lipoprotein; NT-proBNP, N-terminal pro-brain natriuretic
peptide.
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tomography (CT), magnetic resonance imaging (MRI), and dual
X-ray absorptiometry (DEXA) scans.8,13,25,26 However, despite
its value, 24 h urine collection is often considered unreliable,
cumbersome, and are rarely obtained in HF patients.15,16 In a
population-based study, lower spot urinary creatinine was
found to be associated with an increased risk of cardiovascular
events, compared with subjects in the highest tertile, who had
lower risk of developing coronary artery disease, hyperten-
sion, dyslipidaemia, and had a better renal function.27
Furthermore, we recently demonstrated that lower urinary
creatinine measured in spot urine samples was associated
with smaller body dimensions and poor outcomes in chronic
HF.15 Therefore, in the current study, we propose spot urinary
creatinine as an inexpensive and easily quantifiable approach
to identify new onset/worsening HF patients at risk of (sub)
clinical muscle wasting, as well as cachexia, who might benefit
from additional interventions (if possible) to improve
outcomes.
Figure 3 Biomarker position of spot urinary creatinine depicted in a correlation heatmap (index cohort). Abbreviations: Bio-ADM, biologically active
adrenomedullin; BMI, body mass index; CRP, C-reactive protein; FGF23, fibroblast growth factor 23; GDF15, growth differentiation factor 15; GFR, glo-
merular filtration rate; HDL, high density lipoprotein; IL6, interleukin-6; LDL, low density lipoprotein; NT-proBNP, N-terminal pro-brain natriuretic
peptide.
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We showed that lower urinary creatinine concentrations
were associated with smaller body dimensions (lower BMI,
height, and weight) and an increased risk of (>5%) weight
loss at 9 months. Various studies have shown that HF pa-
tients with lower BMI have an increased risk of mortality in
contrast to those with a higher BMI, a phenomenon known
as the obesity paradox.7,28,29 Although the precise underlying
reasons are unclear, one explanation is the fact that lower
BMI may be identifying HF patients with lowered muscle
mass. Cachexia and muscle wasting both have a high preva-
lence of 10–20% in chronic HF and are associated with worse
outcomes.1–4,6 However, the role of muscle wasting in acute/
worsening HF still remains undescribed, and studies show
that more than a third of these patients may exhibit muscle
loss.30,31 Consequently, timely diagnosis of these conditions
may help improve outcomes. However, muscle wasting can-
not be detected using weighing scales alone, as skeletal mus-
cle mass can be replaced by age-related increase in adipose
tissue, and weight can be influenced by presence of oedema
and diuretic treatment.6,10 As a result, spot urinary creatinine
may be an easily accessible approach to distinguish patients
with cachexia and (underlying) muscle wasting. We also
found that patients with lower urinary creatinine had worse
exercise capacity, as shown by a shorter distance walked dur-
ing the 6-min walking test. As severe HF typically manifests
with reduced exercise performance,4 spot urinary creatinine
may also help differentiate patients with reduced muscle
strength in addition to muscle mass and, thus, could serve
as a marker of sarcopenia.
Spot urinary creatinine and outcomes
In our study, we also demonstrated that patients with lower
spot urinary creatinine had a higher risk of mortality or (re-)
hospitalization, most likely driven by more advanced HF
(higher NT-proBNP, worse renal function, and more conges-
tion), as the association was lost after adjustment for the
BIOSTAT risk model. We hypothesize that the association be-
tween urinary creatinine and heart failure severity is driven
by an underlying state of wasting that affects all types of tis-
sues, including fat, bones, and muscles. Although the HF pa-
tients in our study may have co-existent co-morbidities, the
fact that NT-proBNP was associated with urinary creatinine
and weight loss suggests that the state of wasting may be in-
duced due to severe HF. This is also supported by the finding
that urinary creatinine clustered with NT-proBNP, rather than
markers of cachexia (such as IL6, CRP, and haemoglobin) in hi-
erarchical cluster analyses. There are several underlying mech-
anisms of wasting in HF, but the general consensus is that it is
caused by an anabolic-catabolic imbalance. A combination of
hormonal disturbances, release of inflammatory cytokines, re-
duced protein synthesis, and active protein degradation all
contribute to body wasting.6 This, along with a decreased ap-
petite, reduced physical activity, and fatigue further worsens
the wasting state.3,6 As a result, using spot urinary creatinine,
we may be able to identify sicker HF patients with more ad-
vanced disease and a higher risk of wasting.
Overall, findings in the index and the validation cohort
were comparable, and the small differences may be due to
less severe HF in the validation cohort (lesser congestion
and lower NT-proBNP concentrations). Lastly, the value of
spot urinary creatinine assessment in HF has now been vali-
dated across three cohorts, showing a consistent association
of lower urinary creatinine with more severe HF and poor
outcomes.15
Table 3 Univariable logistic regression model for predictors of baseline
log urinary creatinine for the index cohort
Per log urinary creatinine
decrease
OR [CI] P-value
Weight loss (yes/no) 1.14 [1.03–1.27] 0.015
Weight loss >5% 1.23 [1.09–1.39] 0.001
Weight loss >10% 1.20 [1.00–1.43] 0.051
Evans’ criteria for cachexia (yes/no) 1.26 [1.04–1.49] 0.016
Definition Evans’ criteria for cachexia: weight loss>5% from base-
line to 9 months and CRP > 5 mg/L or IL6 > 4 pg/mL,
Hb < 7.45 mmol/L, and albumin <32 d/L.
OR, odds ratio; CI, confidence interval.
Table 4 Cox regression analysis of urinary creatinine for all-cause mortality and combined endpoint for the index cohort
Index cohort
All-cause mortality Combined endpoint
HR [CI] P-value HR [CI] P-value
Urinary creatinine per log decrease 1.27 [1.17–1.38] <0.001 1.23 [1.15–1.31] <0.001
Adjusted for BMI, age, sex, eGFR, and loop diuretic dose at baseline 1.20 [1.09–1.32] <0.001 1.16 [1.08–1.25] <0.001
Adjusted for the above with the addition of the BIOSTAT risk modela 1.03 [0.93–1.15] 0.550 1.01 [0.93–1.10] 0.759
Combined endpoint: age, HF hospitalization in previous year, presence of oedema, log NT-proBNP, systolic blood pressure, haemoglobin,
high-density lipoprotein, sodium, and beta-blocker use at baseline.
BIOSTAT, A systems BIOlogy Study to Tailored Treatment in Chronic Heart Failure; BMI, body mass index; CI, confidence interval; eGFR,
estimated glomerular filtration rate; HR, hazard ratio.
aVariables in the BIOSTAT risk score: All-cause mortality: age, log blood urea nitrogen (BUN), log NT-proBNP, haemoglobin, and
beta-blocker use at baseline.
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Future perspectives
Spot urinary creatinine may be used to identify patients who
could benefit from exercise interventions to improve progno-
sis. Currently, data on the effects of exercise training in acute
HF patients are still scarce, as this patient group is often ex-
cluded from trials due to severity of HF. In the EJECTION-HF
trial, acute HF patients randomized to 24 weeks of supervised
centre-based exercise training showed significant reduction
in all-cause death (based on small number of events), but
no improvement in combined endpoint of all-cause mortality
or readmissions.32 In the REHAB-HF pilot study, a 12-week re-
habilitation programme focused on improving strength,
balance, mobility, and endurance showed a trend towards
improved physical function and decreased hospitalizations
in acute HF patients.33 Recent evidence suggests that
exercise training, combined with nutritional support (e.g. pro-
tein/amino acid supplementation, preventing vitamin/
mineral deficiencies), has shown considerable benefit in
chronic HF patients.6,34 Assessment of urinary creatinine at
baseline and during such studies would be of great interest
to illustrate an improvement of muscle mass during exercise
intervention studies. Lastly, spot urinary creatinine may be in-
corporated in future cachexia and/or sarcopenia definitions
for detecting these conditions in HF patients.
Limitations
Our study is limited by its retrospective design and all results
are observational. As 24 h urinary creatinine was not mea-
sured in BIOSTAT-CHF, correlation between spot urinary cre-
atinine and 24 h urinary creatinine measurements in this
cohort is unknown. Weight at 9 months was not available
in the validation cohort, and we did not use the same
weighing scale for all patients. We could not distinguish in
our study whether weight loss was (un)intentional, caused
by fluid loss or by muscle wasting. Fluid loss caused by di-
uretics may partly have contributed to the association of uri-
nary creatinine with weight loss, as patients with lower
urinary creatinine concentrations had a higher urinary so-
dium/creatinine ratio. However, associations with outcomes
remained significant even after adjusting for baseline loop di-
uretic doses, suggesting a larger effect of muscle loss. An
Figure 4 Kaplan Meier survival curve (index cohort) for combined endpoint (all-cause mortality or HF hospitalization) according to urinary creatinine
value (above/equal to or below the median). Abbreviations: uCR, urinary creatinine.
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important factor to consider when using spot urinary samples
to predict outcomes is that the average creatinine measured
in a spot sample may be higher compared with 24 h measure-
ment at a similar urine specific gravity. Urine osmolarity can
also influence the actual measured concentrations, and we
could not adjust for this.15,16 In dilute urine (urine specific
gravity ≤1.005), spot measurement and 24 h measurement
had a high intraclass correlation of 98.7%. However, in con-
centrated urine (gravity ≥1.020), the correlation decreased
to 26.8%, and values of spot samples were widely
distributed.16 As spot samples may overestimate urinary cre-
atinine concentrations, this is likely to result in an underesti-
mation of the mortality risk in the context of our findings. We
were not able to assess the correlation of urinary creatinine
with advanced body composition imaging techniques such
as CT, MRI, or DEXA, as these were not available in our study.
Future prospective cohort studies and functional analyses are
required to corroborate our results and establish the value of
spot urinary creatinine in new-onset/WHF and to investigate
the effects of interventions to improve muscle mass on spot
urinary creatinine concentrations.
Conclusions
Lower spot urinary creatinine is associated with smaller body
dimensions, renal dysfunction, and more severe HF in pa-
tients with new-onset/WHF. Additionally, lower spot urinary
creatinine is associated with an increased risk of weight loss,
poorer exercise capacity, and a decreased quality of life. Uri-
nary creatinine could therefore be a novel, easily obtainable
marker to assess (risk of) muscle wasting in HF patients.
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